Molecular Characterization and Antimicrobial Susceptibility of Staphylococcus aureus Isolates from Clinical Infection and Asymptomatic Carriers in Southwest Nigeria

PloS One
Olayemi O AyepolaFrieder Schaumburg

Abstract

Few reports from Africa suggest that resistance pattern, virulence factors and genotypes differ between Staphylococcus aureus from nasal carriage and clinical infection. We therefore compared antimicrobial resistance, selected virulence factors and genotypes of S. aureus from nasal carriage and clinical infection in Southwest Nigeria. Non-duplicate S. aureus isolates were obtained from infection (n = 217) and asymptomatic carriers (n = 73) during a cross sectional study in Lagos and Ogun States, Nigeria from 2010-2011. Susceptibility testing was performed using Vitek automated systems. Selected virulence factors were detected by PCR. The population structure was assessed using spa typing. The spa clonal complexes (spa-CC) were deduced using the Based Upon Repeat Pattern algorithm (BURP). Resistance was higher for aminoglycosides in clinical isolates while resistances to quinolones and tetracycline were more prevalent in carrier isolates. The Panton-Valentine leukocidin (PVL) was more frequently detected in isolates from infection compared to carriage (80.2 vs 53.4%; p<0.001, chi2-test). Seven methicillin resistant S. aureus isolates were associated with spa types t002, t008, t064, t194, t8439, t8440 and t8441. The predominant s...Continue Reading

References

Jul 1, 1992·Journal of Clinical Microbiology·O G BrakstadJ A Maeland
Oct 1, 1991·Journal of Clinical Microbiology·K MurakamiS Watanabe
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Jan 4, 2001·The New England Journal of Medicine·C von EiffG Peters
Jan 7, 2003·Applied and Environmental Microbiology·Gerard LinaFrancois Vandenesch
Jun 23, 2005·International Journal of Medical Microbiology : IJMM·Christiane GoerkeChristiane Wolz
Apr 10, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M KaaseS G Gatermann
Aug 3, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S BreurecF Laurent
May 7, 2011·BMC Microbiology·Adebayo O ShittuUlrich Nübel
May 17, 2011·PLoS Neglected Tropical Diseases·Frieder SchaumburgKarsten Becker
May 21, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F SchaumburgK Becker
Oct 30, 2012·The Lancet Infectious Diseases·Laura J ShallcrossAndrew C Hayward
Jan 23, 2014·International Journal of Medical Microbiology : IJMM·Michael Otto
Mar 4, 2014·Current Opinion in Microbiology·Michael Otto
May 28, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F SchaumburgK Becker
Apr 30, 2015·Environmental Microbiology·Ursula KasparKarsten Becker
Mar 1, 2015·Journal of Global Antimicrobial Resistance·Beverly EgyirAnders Rhod Larsen

❮ Previous
Next ❯

Citations

Aug 25, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K V OkudaR Berner
Nov 14, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Leila Akhtar DaneshEhsanollah Ghaznavi-Rad
Aug 28, 2018·Antimicrobial Resistance and Infection Control·Adebayo O ShittuAyodele O Olatimehin
Sep 13, 2017·BMC Infectious Diseases·Birkneh Tilahun TadesseSabine Dittrich

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

R
CC
StaphType
epicalc

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Frieder SchaumburgKarsten Becker
© 2021 Meta ULC. All rights reserved